Ketamine Nasal Spray (Spravato): Cost, How It Works, and What to Expect
At a Glance
- Spravato (esketamine): FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation
- Administration: Self-administered under medical supervision in a certified healthcare setting (REMS program)
- Cost: ~$600-900 per session without insurance; most commercial insurers now cover it with prior authorization
- Treatment schedule: Twice weekly for 4 weeks, then weekly for 4 weeks, then weekly or biweekly for maintenance
- Compounded nasal spray: Off-label racemic ketamine nasal sprays are available at lower cost but lack FDA approval for depression
Understanding Ketamine Nasal Spray: Two Different Products
When people say “ketamine nasal spray,” they could mean one of two things: Spravato (esketamine), the FDA-approved brand-name product from Janssen Pharmaceuticals, or a compounded racemic ketamine nasal spray prepared by a compounding pharmacy. These are not the same product, and the differences in regulation, cost, access, and evidence are significant.
This guide covers both options in detail so you can have an informed conversation with your provider. For a broader overview of ketamine-based treatments, see our ketamine therapy guide. For cost comparisons across all ketamine formats, visit our ketamine therapy cost breakdown.
Spravato (Esketamine): The FDA-Approved Option
What Is Esketamine?
Esketamine is the S-enantiomer of ketamine. Standard ketamine is a racemic mixture, meaning it contains equal parts of two mirror-image molecules: S-ketamine and R-ketamine. Janssen isolated the S-enantiomer because it binds to NMDA receptors with roughly 3-4 times greater affinity than the R-enantiomer, which theoretically allows for lower doses with stronger antidepressant effects.
The FDA approved Spravato in March 2019 for treatment-resistant depression (TRD), defined as depression that has failed to respond to at least two adequate trials of antidepressant medications. In August 2020, the indication expanded to include major depressive disorder (MDD) with acute suicidal ideation or behavior.
How Spravato Works
Like all forms of ketamine, esketamine works primarily by blocking NMDA (N-methyl-D-aspartate) receptors. This triggers a cascade of downstream effects:
- Increased brain-derived neurotrophic factor (BDNF) release
- Activation of AMPA receptors
- Stimulation of mTOR signaling pathway
- Rapid synaptogenesis (formation of new synaptic connections)
The net result is rapid restoration of synaptic connectivity in brain regions damaged by chronic depression, particularly the prefrontal cortex and hippocampus. This is fundamentally different from traditional antidepressants, which work by modulating serotonin, norepinephrine, or dopamine levels and take weeks to show effect.
The REMS Program: What Administration Looks Like
Spravato is available only through a restricted program called the Spravato REMS (Risk Evaluation and Mitigation Strategy). This was implemented because of concerns about dissociation, sedation, and potential misuse.
Here is what a typical treatment session involves:
Before arrival: Avoid food for 2 hours and liquids for 30 minutes prior to dosing. If you use a nasal corticosteroid or decongestant, use it at least 1 hour before.
At the clinic: You self-administer the nasal spray under the direct observation of a healthcare provider. The device delivers a fixed dose per spray. A typical treatment session involves 2 or 3 devices (56 mg or 84 mg total dose).
Monitoring period: You must remain at the healthcare facility for at least 2 hours after dosing. Staff will check your blood pressure at approximately 40 minutes and again before discharge. Dissociation, if it occurs, typically peaks within 30-40 minutes and resolves within 1-2 hours.
After discharge: You cannot drive or operate heavy machinery for the rest of the day. You will need someone to drive you home.
- Induction (Weeks 1-4): 56 mg or 84 mg, twice per week
- Maintenance (Weeks 5-8): 56 mg or 84 mg, once per week
- Long-term maintenance (Week 9+): 56 mg or 84 mg, once weekly or once every 2 weeks
Most patients start at 56 mg and increase to 84 mg based on response and tolerability.
Spravato Cost and Insurance Coverage
Cost is one of the biggest barriers to Spravato. The medication itself, the required monitoring period, and the clinical setting all contribute to per-session costs that can be substantial.
| Cost Component | Without Insurance | With Insurance (typical) |
|---|---|---|
| Spravato medication (per session) | $590-890 | $0-150 copay |
| Facility/monitoring fee | $100-300 | Often covered |
| First month total (8 sessions) | $5,500-9,500 | $0-1,200 |
| Annual maintenance (biweekly) | $15,000-30,000 | $0-3,600 |
As of 2026, most major commercial insurers cover Spravato with prior authorization. The prior auth process typically requires documentation of two failed antidepressant trials and a current diagnosis of TRD or MDD with suicidal ideation. Medicare and many Medicaid plans also provide coverage, though formulary tiers vary by state.
Janssen offers a savings program (the Spravato Savings Program) that can reduce out-of-pocket costs to as low as $10 per session for commercially insured patients. Uninsured patients may qualify for the Janssen CarePath program for financial assistance.
Compounded Ketamine Nasal Spray: The Off-Label Alternative
Compounding pharmacies can prepare racemic ketamine nasal sprays at a fraction of the cost. These are prescribed off-label by physicians, typically psychiatrists or ketamine clinic providers.
Key differences from Spravato:
- Contains racemic ketamine (both S and R enantiomers), not isolated esketamine
- Not FDA-approved for depression
- Does not require the REMS program or in-office monitoring (though responsible providers may still require initial supervised sessions)
- Can be used at home once the patient demonstrates tolerability
- Significantly less expensive
A typical compounded ketamine nasal spray costs $50-150 per month, making it vastly more affordable than Spravato. The tradeoff is the lack of Phase III clinical trial data and the absence of regulatory oversight specific to this formulation.
Compounded ketamine nasal sprays are not “generic Spravato.” They contain a different molecule (racemic ketamine vs. esketamine), are compounded to different specifications, and lack the clinical trial infrastructure that supports Spravato. Some emerging research suggests R-ketamine may have unique antidepressant properties of its own, potentially making racemic ketamine a broader-spectrum treatment. But this remains an active area of investigation.
Side Effects and Safety
Both Spravato and compounded ketamine nasal spray share similar side effect profiles, though the severity and frequency may differ:
Common side effects (occurring in 20-40% of patients):
- Dissociation (feeling detached from your body or surroundings)
- Dizziness
- Nausea
- Sedation
- Increased blood pressure (transient, usually resolves within 2 hours)
- Altered sense of taste
Less common side effects:
- Anxiety during or after the session
- Headache
- Vertigo
- Blurred vision
- Nasal discomfort
Dissociation is the most discussed side effect. Most patients describe it as a mild floating sensation or feeling of detachment that resolves within 60-90 minutes. Some find it unpleasant; others find it neutral or even therapeutic. Providers can adjust the dose to manage dissociation while maintaining antidepressant efficacy.
Who Is a Candidate?
For Spravato specifically, FDA labeling limits its use to adults with TRD or MDD with suicidal ideation, in conjunction with an oral antidepressant. Compounded ketamine nasal spray is prescribed more broadly, including for anxiety, PTSD, OCD, chronic pain, and depression that has not met the strict TRD definition.
People who should not use either product include those with uncontrolled hypertension, aneurysmal vascular disease, history of intracerebral hemorrhage, or active psychosis. A history of substance use disorder requires careful evaluation but is not an absolute contraindication.
What to Expect During Your First Session
Whether you are starting Spravato through the REMS program or beginning compounded ketamine nasal spray with supervised initiation, here is a realistic timeline for your first experience:
0-5 minutes: Self-administer the nasal spray. Each nostril receives one spray per device. You may taste a slight bitterness in the back of your throat.
5-15 minutes: Light-headedness and mild perceptual changes may begin. Some people feel warmth or tingling.
15-40 minutes: Peak effects. Dissociation, if present, is strongest during this window. Many patients prefer to lie down with an eye mask. Music can be helpful.
40-90 minutes: Effects gradually subside. Most people feel grounded again within an hour of peak onset.
90-120 minutes: Clinical assessment, blood pressure check, and discharge (for Spravato REMS). You may feel tired or mentally quiet for the rest of the day.
Frequently Asked Questions
How quickly does Spravato work for depression?
Many patients notice improvement within the first week, sometimes after just 1-2 sessions. This rapid onset is one of the primary advantages over traditional antidepressants, which typically require 4-6 weeks. Clinical trials showed statistically significant improvement as early as 24 hours after the first dose.
Can I stop my other antidepressant while on Spravato?
Spravato is FDA-approved as an adjunct to oral antidepressant therapy, not a replacement. Most providers recommend continuing your current oral antidepressant during Spravato treatment. Any changes to your medication regimen should be discussed with your prescriber.
Is ketamine nasal spray addictive?
Ketamine has abuse potential, which is one reason Spravato carries the REMS requirement. At prescribed doses and frequencies, the risk of physical dependence is low. Psychological dependence is possible, particularly in patients with a history of substance use disorders. Responsible prescribing includes regular reassessment and structured treatment plans.
How long do the effects of each treatment last?
Antidepressant effects from a single session typically last 3-7 days during the induction phase. As treatment progresses and synaptic remodeling consolidates, the interval between treatments can often be extended. Some patients eventually maintain remission with sessions every 2-4 weeks.
What is the difference between Spravato and IV ketamine?
Spravato is esketamine (S-enantiomer) delivered intranasally. IV ketamine infusions use racemic ketamine delivered intravenously. IV infusions allow for more precise dose titration and generally produce faster onset of effects. Spravato has the advantage of FDA approval, potential insurance coverage, and no need for IV access. Both are effective for depression. See our full comparison in the ketamine therapy guide.
Can I use a compounded nasal spray at home?
Yes. After initial supervised sessions to establish tolerability, many providers prescribe compounded ketamine nasal spray for home use. Home-use protocols typically include specific instructions about timing, environment, and having someone nearby during the first several sessions. Not all providers are comfortable with at-home use, so discuss this with your prescriber.
